Regurolix in combinations other than degurolix – pro
Regurolix is a fairly newly abvaialble drug and is only now beginning to e studied with other agents. As of now, it is not supported by the literature.
Jose De La Cerda, Elizabeth Migoya, Bruce Brown, Sophia Lu, Fabian Zohren, Ronald F. Tutrone, and Curtis Dunshee, Relugolix in combination with abiraterone acetate, apalutamide, or docetaxel in men with advanced prostate cancer (aPC): A phase 1, three-part, open-label, parallel-cohort study. JOCO Prostate Cancer – Advanced
February 16, 2022. This study nis ongoing: Screening for Part 2 was initiated in August 2021 and for Part 3 it is expected to initiate in February 2022.
Clinical trial information: NCT04666129.
D. J. George et al, mpact of Concomitant Prostate Cancer Medications on Efficacy and Safety of Relugolix Versus Leuprolide in Men With Advanced Prostate Cancer.Clinical Genitourinary Cancer Volume 21, Issue 3, June 2023, Pages 383-392.e2